Agenus Inc
Agenus Inc (AGEN) Historical Volatility
AGEN's 30 day historical volatility is 77.25%, in the 25th percentile of readings over the past year. This is a low percentile, meaning Agenus Inc shares have been calmer than usual. AGEN's 30 day implied volatility sits at 84.70%, with an IV Rank of 2.38%, leaving IV 7.45 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 19, 2026.
Read more
Tracking AGEN historical volatility helps you see how much Agenus Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AGEN's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AGEN 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AGEN's 30 day historical volatility, or AGEN HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AGEN's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody.
Historical Volatility
Historical movement is subdued versus the past year. The stock has been unusually quiet.
As of Nov 19, 2026
As of Nov 19, 2026
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →